Francesca Lunghi

Milan, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy.

Long-term safety and efficacy of ponatinib in intolerant chronic myeloid leukemia: subanalysis of the observational study of Iclusig® (ponatinib) treatment in patients with chronic myeloid leukemia in Italy.

Journal: Haematologica

Published: January 23, 2026

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study.

Journal: Cancer

Published: November 16, 2025

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Clinical Outcomes of Ruxolitinib Treatment in Patients With IPSS Intermediate-1-Risk Myelofibrosis: Interim Analysis From an Italian, Prospective Study (ROMEI).

Journal: Hematological oncology

Published: November 13, 2025

The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

The 2024 Three-Strata Baseline Anemia Definition of the Revised IWG-ELN Criteria Dissects Survival in Ruxolitinib-Treated Myelofibrosis Patients.

Journal: American journal of hematology

Published: March 05, 2025

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).

Journal: Cancer

Published: October 24, 2024

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Direct determination of chronic myeloid leukemia prevalence in Lombardy-Italy: Global implications.

Journal: Hematological oncology

Published: August 09, 2024

Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.

Bosutinib Treatment of Chronic Myeloid Leukemia in Lombardy.

Journal: Acta haematologica

Published: April 28, 2024

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

Choice of Frontline Tyrosine-Kinase Inhibitor and Early Events in Very Elderly Patients With Chronic Myeloid Leukemia in Chronic Phase: A "Campus CML" Study.

Journal: European journal of haematology

Published: March 11, 2024

Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.

Use of defibrotide in COVID-19 pneumonia: comparison of a phase II study and a matched real-world cohort control.

Journal: Haematologica

Published: February 27, 2024

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera.

Journal: NEJM evidence

Published: February 06, 2024

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.

The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan.

Journal: Clinical lymphoma, myeloma & leukemia

Published: December 08, 2023

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.

Journal: Annals of hematology

Published: November 13, 2023

Showing 1-12 of 49

Last Updated: 09/26/2026